StreetInsider.com News Articles

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.

The analyst commented: "RNTX reported a meaningful set of 1Q26 updates, with the most important development being the post-quarter $57.5M common-stock financing, which we believe materially changes the stock setup by removing the largest overhang on the story and funding the ongoing RENEW Phase 2 trial of LTI-03 in IPF through completion. The regulatory overhang had already largely cleared with the FDA allowing the Phase 2 program to resume and the

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.

Form 4 Rein Therapeutics, Inc. For: May 21 Filed by: VON RICKENBACH JOSEF H

Thu, 28 May 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20260528/26569382.html

Form 4 Rein Therapeutics, Inc. For: May 21 Filed by: VON RICKENBACH JOSEF H

Thu, 28 May 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20260528/26569382.html

Form PRE 14A Rein Therapeutics, Inc. For: Jul 20

Thu, 28 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260528/26568421.html

Form PRE 14A Rein Therapeutics, Inc. For: Jul 20

Thu, 28 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260528/26568421.html

Rein Therapeutics closes $57.5 million stock offering

Mon, 18 May 2026 08:01:09 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) completed its underwritten public offering of common stock, raising $57.5 million in gross proceeds before fees and expenses, according to a company statement.

The clinical-stage biopharmaceutical company sold 57.5 million shares at $1.00 per share. The transaction included the full exercise of underwriters' over-allotment option to purchase an additional 7.5 million shares.

The offering consisted solely of common stock with no warrants or derivative securities issued. Investors included Adar1 Capital Management LLC, Ikarian Capital LLC, Bios Partners, Stonepine Capital Management, Cable Car Capital LP, and Second Line Capital.

Rein plans to use proceeds to fund its Phase 2

Rein Therapeutics closes $57.5 million stock offering

Mon, 18 May 2026 08:01:09 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) completed its underwritten public offering of common stock, raising $57.5 million in gross proceeds before fees and expenses, according to a company statement.

Rein plans to use proceeds to fund its Phase 2

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters’ over-allotment option. The financing included new and existing healthcare-focused investors, including Adar1

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

Form 10-Q Rein Therapeutics, Inc. For: Mar 31

Fri, 15 May 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20260515/26499643.html

Form 10-Q Rein Therapeutics, Inc. For: Mar 31

Fri, 15 May 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20260515/26499643.html

Form 4 Rein Therapeutics, Inc. For: Apr 30 Filed by: WINDSOR JAMES BRIAN

Wed, 13 May 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260513/26482544.html

Form 4 Rein Therapeutics, Inc. For: Apr 30 Filed by: WINDSOR JAMES BRIAN

Wed, 13 May 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260513/26482544.html

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: BIOS Fund I, LP

Fri, 08 May 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260508/26459490.html

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: BIOS Fund I, LP

Fri, 08 May 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260508/26459490.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: Lynwood Capital Management Inc.

Fri, 08 May 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26458718.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: Lynwood Capital Management Inc.

Fri, 08 May 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26458718.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: Funicular Funds, LP

Thu, 07 May 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260507/26455634.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: Funicular Funds, LP

Thu, 07 May 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260507/26455634.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Wed, 06 May 2026 13:30:00 -0400

si-local-file:///var/storage/secattach/20260506/26442410.html

Form SCHEDULE 13G Rein Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Wed, 06 May 2026 13:30:00 -0400

si-local-file:///var/storage/secattach/20260506/26442410.html

Form 8-K Rein Therapeutics, Inc. For: Apr 30

Mon, 04 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260504/26425767.html